Â鶹ŮÓÅ

In the latest attempt to restore confidence in its business, the embattled Silicon Valley blood-testing company Theranos is replacing its chief operating officer and expanding its board, including the addition of a former senior Amgen executive. Theranos attracted the media spotlight with its claim of revolutionizing the laboratory business, offering simplified blood tests at a fraction of the cost of conventional methods. But the company, once valued at $9 billion, now faces growing skepticism over its technology and is under criminal investigation and intense regulatory scrutiny. (Abelson, 5/11)

A top executive who helped build Theranos Inc. into a major blood-testing laboratory is leaving the company amid regulatory probes of the embattled Silicon Valley firm. The departure of Sunny Balwani as Theranos president and chief operating officer comes amid a broader board reorganization announced by the Palo Alto, Calif., firm. In a release late Wednesday, Theranos said it is expanding its board, adding three members to beef up its scientific and medical expertise. (Carreyrou, 5/11)

Theranos said Wednesday that Sunny Balwani, its president and chief operations officer, is leaving the company. The firm will also add three new board members as part of the restructuring. Theranos has positioned itself as a provider of cheaper, more efficient alternatives to traditional medical tests. It had been valued at more than $9 billion on claims that it can process dozens of lab tests with just a few drops of blood. (Mclean, 5/12)